Volker Hartmann/Getty Images
For the past few years, pharma giant Bayerhas transformed its pipeline by acquiring multiple cell and gene therapy companies to create new opportunities. This has allowed the company to provide life-saving and life-altering therapies to patients with different disease types.
The new approach has energized the Germany-based life sciences giant known for inventing aspirin, its leading position in chemistry and the advancement of small molecules. Through multiple acquisitions, Bayer has bolted on new cutting-edge programs in four key areas of focusiPSC, allogenic CAR-T, genome mutations, and gene editing. One year ago, Marianne De Backer, Ph.D., head of business development & licensing in Bayers pharmaceuticals division,told BioSpace that Bayer had to find pioneers in these fields and bring them into the fold to achieve its transformative goal. Themove is beginning to show the fruit that will validate that decision.
On Tuesday, Christian Rommel, Ph.D., head of research and development t at Bayer, told BioSpace that he credits the Bayer leadership team for the courage and vision to lead the storied company through a new era. Rommel joined Bayer in early 2021 after spending seven years at Rochein various roles, including global head of oncology pharma research & early development. He was attracted to the companys changes with the launch of the cell and gene therapy platform developed within its pharmaceutical division. The 150-year-old company established the platform to advance new approaches to treating a myriad of diseases.
We are reinventing our story and becoming strong in new areas of the sciences, Rommel said. We look very different than we did a year ago.
Rommel spoke to BioSpace the day after the company forged a collaboration with Mammoth Biosciences for theirCRISPR technology expected to be used to develop in vivo gene-editing therapies. The companies plan to harness the CRISPR technology across five preselectedin vivoindications, with the first focus on liver-targeted diseases. Rommel expressed his excitement about the potential of CRISPR technology and the promise that it can provide for patients with rare diseases.
The Mammoth technology is a therapeutic approach in its own right. We will consider enabling that approach and plan to build a pipeline with them, he said.
The potential that technology like CRISPR and other cell and gene therapy approaches offers to patients has had Bayer excited enough to open the purse strings and bolster its pipeline.
You need a little bit of financial resources to keep innovating, Rommel quipped. He then noted that these kinds of approaches have broken new ground in medicine and offer a glimmer of hope in developing cures for devastating diseases. There is high risk in cell and gene therapy. But the rewards are promising.
Rommel pointed to Bayer subsidiary BlueRock Therapeutics,acquired in 2019, and its pluripotent stem cell-derived dopaminergic neuron study in Parkinsons disease. Last week, BlueRock closed out its first two cohorts in an open-label Phase I study. Ultimately, the company hopes its approach will replace lost neurons in the midbrain region of Parkinsons disease patients. This could regenerate lost function in the brain and potentially reverse the disease.
With BlueRock, were doing something that makes a lot of sense, but is so hard to do, Rommel said. He said they are committed to the programbut recognize that there are still hurdles to overcome.
In addition to BlueRock, Bayer also acquired AskBio in 2020 and partnered with Atara Biotherapeuticsto develop off-the-shelf T-cell immunotherapies for high mesothelin-expressing tumors.And, just a few months ago, Bayer snapped up San Diego-based Vividion Therapeuticsand its protein surface screening program. Rommel said the acquisition of Vividion will become a cornerstone of its new strategy to develop innovative therapies. Vividions technology platform uses chemoproteomics, chemistryand biologyto find drug targets in previously undruggable proteins.
Rommel is keen on Vividions position under the Bayer umbrella. He said the innovation taking place at Vividion combined with the muscle of Bayer would lead to the development of first-in-class drug candidates that can provide new therapies for patients who are not well-served by existing treatments.
Its a very good strategic fit, he said.
As part of its evolution, Bayer has taken a different approach with its recent acquisitions. The companies are brought under the Bayer umbrella, but they operate independently, at arms length. This approach aims to let companies maintain that sense of independenceto foment entrepreneurial and scientific cultures. And thats an approach that is paying off. Rommel disclosed that Bayers arms length approach appealed to Vividion. The company had been in the midst of an initial public offering when Bayer approached them with the acquisition offer. The San Diego company ultimately dropped the plans to go public to come under the Bayer umbrella.
Vividion can be Vividion. They can do the innovative discovery work they set out to do, he said.
While Bayer continues to assess mergers and acquisitions to advance its new cell and gene therapy division, Rommel noted that the coming months will be crucial as data come infrom various programs the company has bought into with its aggressive investment strategy. He noted the company would have successes and failures, but what they learn from both will lead to better innovations for patients.
For any R&D organization, its important to do this kind of work because its so inspirational and aspirational, he said.
Read the original here:
Legendary Bayer is Reinventing its Story with Cell and Gene Therapy - BioSpace
- 100 plus years of stem cell research20 years of ISSCR - PMC - March 26th, 2024
- Stem Cell Science and Human Research Studies Ahead of Cargo Arrival - NASA Blogs - February 18th, 2024
- Stem cell research project to launch into space - Fox Weather - January 24th, 2024
- Breakthrough in cancer research opening up stem cell therapy to more people. How you can get involved - 69News WFMZ-TV - January 20th, 2024
- Stem Cell Research Heading to the ISS on Axiom Mission 3 - ISS National Lab - January 18th, 2024
- No, Rep. Steve Scalise Didn't Vote Against Stem Cell Research From Which He Is Now Benefiting - The Dispatch - January 12th, 2024
- Applications are open for the Maryland Stem Cell Research Fund - Technical.ly - January 4th, 2024
- Global Stem Cell Therapy Market to Reach USD 928.6 Million by 2031: Says Allied Market Research - Yahoo Finance - November 19th, 2023
- Current state of stem cell-based therapies: an overview - PMC - November 3rd, 2023
- Dynamic Stem Cell Therapy Uncovers Research in Advance Regenrative Medicine - Yahoo Finance - November 3rd, 2023
- Research Fellow (Aging and Cancer Stem Cell Laboratory ... - Times Higher Education - October 15th, 2023
- Qkine Collaborates with the Cambridge Stem Cell Institute to Facilitate Same-Day Access to Key Research Products for Researchers at the Cambridge... - September 27th, 2023
- Stem cells: a comprehensive review of origins and emerging clinical ... - September 25th, 2023
- Stem Cell Research and Communicating Science | GBH - GBH News - September 20th, 2023
- Stem cell research reveals the earliest stages of a human life - SBS News - September 10th, 2023
- Stem Cell Therapy Market Size 2023 | Innovative Research Methodologies with Emerging Trends and Opportuni - Benzinga - September 10th, 2023
- Autologous Stem Cell and Non-Stem Cell Based Therapies Market Research, Current Trends, Key Industry Play - Benzinga - September 8th, 2023
- Stem Cell Therapy Market 2023 Business Statistics and Research ... - The Knox Student - August 28th, 2023
- Autologous Stem Cell Based Therapies Market Analysis, Research ... - Chatfield News-Record - July 19th, 2023
- Global Stem Cell Market Projected to Reach $14 Bn by 2028: Ken Research - Yahoo Finance - July 11th, 2023
- Theradaptive Awarded Manufacturing Assistance Grant by the Maryland Stem Cell Research Fund - Benzinga - July 10th, 2023
- Bionano Announces Presentation of OGM Utility Across Stem Cell Therapy Applications at the International Society for Stem Cell Research (ISSCR) Annual... - June 19th, 2023
- Sana Biotechnology Highlights Preclinical Data from Hypoimmune and Fusogen Platforms at the International Society for Stem Cell Research (ISSCR) 2023... - June 17th, 2023
- Induced Pluripotent Stem Cell (iPSC) Global Market Report 2023: Effective Research Programs Hold Key in Roll Out of Advanced iPSC Treatments - Yahoo... - June 17th, 2023
- Lung and heart stem cell research paves way for new COVID-19 treatments - Medical Xpress - June 14th, 2023
- Toxicology PhD student cultivating giant leaps in stem cell research ... - June 4th, 2023
- Harvard Stem Cell Institute (HSCI) - May 26th, 2023
- Findings may lead to improved insulin-secreting cells derived from stem ... - May 26th, 2023
- Cell Press: Stem Cell Reports - May 26th, 2023
- Stem cell research could enable blood to be made in other parts of the body - Medical Xpress - May 26th, 2023
- Construction of myocardial patch with mesenchymal stem cells and poly ... - May 22nd, 2023
- Cedars-Sinai to Send Stem Cells to the Space Station to Aid in the ... - May 22nd, 2023
- researchers expand human blood stem cells | Institute for Stem Cell ... - May 22nd, 2023
- A Look Inside Stem Cells Helps Create Personalized Regenerative ... - May 17th, 2023
- Exclusive Research Report on Msenchymal Stem Cell and Exosome Diagnostics and Therapies Market to Witness Comp - openPR - May 17th, 2023
- The Future of Stem Cell Research: Master of Science in ... - The Daily | Case Western Reserve University - May 10th, 2023
- Exclusive Research Report on Stem Cell Therapy for Diabetes and ... - Digital Journal - May 9th, 2023
- Aging melanocyte stem cells and gray hair | National Institutes of ... - May 5th, 2023
- Mouse hair turns gray when certain stem cells get stuck - May 5th, 2023
- Science-First Skincare Company Michal Morrison Secures Exclusive World-Wide License of Proprietary STEM6 Molecule, Supported by Over 25 Years of... - May 5th, 2023
- BioCentriq and panCELLa execute research agreement to study stem cell-derived Natural Killer cell expansi - Benzinga - May 3rd, 2023
- Hair turning gray? Study finds a stem cell 'glitch' may be the cause - May 1st, 2023
- Elevai Labs Announces Research Grant Award and Partnership to Better Characterize the 'Payload' of ELEVAI's Stem Cell-derived Exosomes - Yahoo Finance - April 27th, 2023
- Why does hair turn gray? A new study says 'stuck' stem cells may ... - NPR - April 27th, 2023
- Study advances understanding of how melanocyte stem cells work to color ... - April 21st, 2023
- Stem cell research and therapy legislation to be replaced, says ... - Bahamas Tribune - April 21st, 2023
- Stem Cell Research (journal) - Wikipedia - April 21st, 2023
- Scientists Are About to Try to Create Stem Cells in Space - April 21st, 2023
- Stem Cell Research & Therapy | Articles - BioMed Central - April 16th, 2023
- Stem Cell Junk Yards Reveal a New Clue About Aging | WIRED - April 16th, 2023
- Global Stem Cells Market Research Report 2023: Implications - April 16th, 2023
- Stem cell research can help people with hard- | EurekAlert! - April 16th, 2023
- University Of Edinburgh's stem cell research gets funding boost - India Education Diary - April 14th, 2023
- Two major stem cell research projects supported with more than ... - University of California, Santa Cruz - April 8th, 2023
- Cancer detection predicts tumors before they form: discovery - March 29th, 2023
- Stem cell therapy: a potential cure for hearing loss? - March 29th, 2023
- Turkey's Only Stem Cell Production Application and Research Center - Expat Guide Turkey - March 24th, 2023
- Stem Cell Research Article, Embryonic Cells Information, Cell Therapy ... - March 24th, 2023
- Scientists create mice with cells from 2 males for 1st time - March 19th, 2023
- QBRI concludes stem cells symposium - Gulf Times - March 17th, 2023
- 2020 California Proposition 14 - Wikipedia - March 17th, 2023
- Stem Cell Reports | Journal | ScienceDirect.com by Elsevier - March 17th, 2023
- Stem cell therapy MSC-NP found to ease inflammatory activity of brain ... - March 12th, 2023
- Stem Cell Research | Office of Research Compliance | SIU - March 12th, 2023
- Heart disease study shows hope for stem cell treatment - March 4th, 2023
- Stem cells drive antler regeneration | Science - March 4th, 2023
- Stem Cell Research: Argumentative Essay - Free Essay Example - Edubirdie - March 4th, 2023
- Stem Cell Research | Thermo Fisher Scientific - US - March 4th, 2023
- Stem cell controversy - Wikipedia - February 28th, 2023
- National Institutes of Health grant funds interdisciplinary ... - February 27th, 2023
- Research Associate in Cancer Stem Cell Research job with ... - Times Higher Education - February 25th, 2023
- Pioneering Stem Cell Research Conference at The Aga Khan ... - The Aga Khan University - February 25th, 2023
- Scientists grapple with ethics of stem cell research - STAT - February 17th, 2023
- Research Associate in Stem Cell Neurobiology job with KINGS ... - Times Higher Education - January 30th, 2023
- Stem cells: past, present, and future | Stem Cell Research & Therapy ... - January 12th, 2023
- Edu Thesis & Essay: Stem cell research outline top writers online! - January 12th, 2023
- Stem Cell Biology Research Program | Johns Hopkins Institute for Cell ... - January 5th, 2023
- Stem cell population identified is vital for bone regeneration: Research - ThePrint - January 5th, 2023
- Leading scientist 'blown away' by UAE advances in stem cell research - The National - December 15th, 2022
- The Stem Cell Assay Market Is Set To Grow At A 20% Annual Rate, Due To The High Prevalence Of Chronic Diseases As Per The Business Research Company's... - December 13th, 2022
Recent Comments